Bio-Techne set and validated its science-based remission reduction targets with a diverse multidisciplinary team including Erin Woodward, Michelle Eul, Anna Weispfenning, Alyssa Mason, Laurie Gilman, Carolin Spiegel, Jennifer Moore, Lindsey Rodger, Gary Latham, David Clair, CFA, MBA, Mary Anne Mashl Williams, Ken Fairleigh, Rachel Esbjornsson, Sarah Gatherum, Andrea LaGrone, and Cheryl Bethune.

Bio-Techne is a global life sciences company that empowers scientific discovery and advances human health. Through its industry-leading branded product portfolios, including R&D Systems™ by Bio-Techne, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, the company delivers high-quality solutions and expert support that enable scientists and clinicians to make breakthrough discoveries, develop and manufacture novel therapeutics and deliver precision diagnostics across cancer research, neuroscience, diabetes, rare diseases, and beyond. Bio-Techne®, Bio-Techne Diagnostics™, Bio-Techne Spatial ™, R&D Systems™ are trademarks or registered trademarks of Bio-Techne Corporation and affiliated entities. All other trademarks, service marks, and trade names are the property of their respective owners.